MindWalk Holdings (HYFT) Share-based Compensation (2023 - 2026)
MindWalk Holdings (HYFT) posted quarterly Share-based Compensation of $590899.9 for Q2 2026, up 1486.54% year-over-year from $37244.6 in Q2 2025, and up 217.85% quarter-over-quarter from $185907.0 in Q1 2026.
MindWalk Holdings (HYFT) Share-based Compensation (2023 - 2026) Analysis & Trends
MindWalk Holdings (HYFT) has reported Share-based Compensation for 4 consecutive years, with $590899.9 the latest figure, recorded in Q2 2026.
- In Q2 2026, Share-based Compensation rose 1486.54% year-over-year to $590899.9; the TTM figure through Apr 2026 stood at $932313.6 (up 189.52% YoY), while the FY2026 annual figure was $930120.2, up 191.15% from the prior year.
- Share-based Compensation rose to $590899.9 in Q2 2026 per HYFT's latest filing, from $185907.0 in the prior quarter.
- Across five years, Share-based Compensation topped out at $662284.6 in Q3 2025 and bottomed at -$506777.9 in Q4 2025.
- Historically, Share-based Compensation has averaged $214968.3 across 4 years, with a median of $158940.7 in 2023.
- Annual changes were most pronounced in 2025 — Share-based Compensation tumbled 540.79% — and 2026, when it jumped 1486.54%.
- MindWalk Holdings' Share-based Compensation stood at $219035.7 in 2023, then tumbled by 47.51% to $114969.3 in 2024, then sank by 540.79% to -$506777.9 in 2025, then soared by 216.6% to $590899.9 in 2026.
- Business Quant data shows HYFT's Share-based Compensation at $590899.9 in Q2 2026, $185907.0 in Q1 2026, and -$506777.9 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 83.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 590,899.88 |
| Apr 30, 2026 | 590,899.88 |
| Jan 31, 2026 | 185,906.98 |
| Jan 31, 2026 | 185,906.98 |
| Oct 31, 2025 | -506,777.94 |
| Oct 31, 2025 | -506,777.94 |
| Jul 31, 2025 | 662,284.65 |
| Jul 31, 2025 | 662,284.65 |
| Apr 30, 2025 | 37,244.62 |
| Apr 30, 2025 | 37,244.62 |
| Jan 31, 2025 | 49,309.88 |
| Jan 31, 2025 | 49,309.88 |
| Oct 31, 2024 | 114,969.33 |
| Oct 31, 2024 | 114,969.33 |
| Jul 31, 2024 | 120,501.48 |
| Jul 31, 2024 | 120,501.48 |
| Apr 30, 2024 | 174,792.31 |
| Apr 30, 2024 | 174,792.31 |
| Jan 31, 2024 | 131,670.42 |
| Jan 31, 2024 | 131,670.42 |